1. Signaling Pathways
  2. GPCR/G Protein
    Neuronal Signaling
  3. Cannabinoid Receptor

Cannabinoid Receptor

Cannabinoid Receptor

Cannabinoid receptors are currently classified into three groups: central (CB1), peripheral (CB2) and GPR55, all of which are G-protein-coupled. CB1 receptors are primarily located at central and peripheral nerve terminals. CB2 receptors are predominantly expressed in non-neuronal tissues, particularly immune cells, where they modulate cytokine release and cell migration. Recent reports have suggested that CB2 receptors may also be expressed in the CNS. GPR55 receptors are non-CB1/CB2 receptors that exhibit affinity for endogenous, plant and synthetic cannabinoids. Endogenous ligands for cannabinoid receptors have been discovered, including anandamide and 2-arachidonylglycerol.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-157833
    Heptadecanoyl ethanolamide
    Inhibitor 99.0%
    Heptadecanoyl ethanolamide is an endogenous cannabinoid. Heptadecanoyl ethanolamide is a synthetic analog of PEA which incorporates an odd-numbered (17-carbon) fatty acid chain.
    Heptadecanoyl ethanolamide
  • HY-112707
    AM9405
    Agonist
    AM9405 is a novel peripherally active cannabinoid type 1 (CB1) and serotonin type 3 receptor agonist. AM9405 inhibits twitch contraction of the ileum and the colon with IC50s of 45.71 and 0.076 nM, respectively.
    AM9405
  • HY-10863S1
    Anandamide-d11
    99%
    Anandamide-d11 is deuterium labeled Anandamide. Anandamide is an immune modulator in the central nervous system acts via not only cannabinoid receptors (CB1 and CB2) but also other targets (e.g., GPR18/GPR55).
    Anandamide-d<sub>11</sub>
  • HY-B1161AR
    S-Methoprene (Standard)
    Antagonist
    2-Methyl-3-(trifluoromethyl)aniline (Standard) is the analytical standard of 2-Methyl-3-(trifluoromethyl)aniline. This product is intended for research and analytical applications. 2-Methyl-3-(trifluoromethyl)aniline is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    S-Methoprene (Standard)
  • HY-N1415S1
    β-Caryophyllene-13C,d2
    Agonist
    β-Caryophyllene-13C,d2 is 13C and deuterated labeled β-Caryophyllene (HY-N1415). β-Caryophyllene is a CB2 receptor agonist.
    β-Caryophyllene-<sup>13</sup>C,d<sub>2</sub>
  • HY-147707
    CB2 receptor antagonist 1
    Hexyl resorcinol derivative 29 has been proved to be a CB2 selective competitive antagonist / reverse agonist with good potency. Olivanol and 5- (2-methyloctane-2-yl) resorcinol derivatives 23 and 24 showed significant antinociceptive activity. Compound 24 was shown to activate cannabinoid and TRPV1 receptors.
    CB2 receptor antagonist 1
  • HY-110194
    Virodhamine TFA
    Modulator
    Virodhamine TFA is an endocannabinoid, it regulates neurotransmission by activating the cannabinoid (CB) receptors. Virodhamine is an antagonist of CB1 receptor and an agonist of CB2 receptor. Virodhamine TFA induces megakaryocytic differentiation by triggering MAPK signaling and ROS production. Virodhamine TFA can be used for the research of various neurological disorders such as Alzheimer's and Parkinson's diseases.
    Virodhamine TFA
  • HY-148909
    Isopropyl dodec-11-enylfluorophosphonate
    Inhibitor
    Isopropyl dodec-11-enylfluorophosphonate (IDEFP) is an organophosphorus ester that antagonizes the central cannabinoid receptor (CB1) and inhibits FAAH with similar potencies (IC50 = 2 nM).
    Isopropyl dodec-11-enylfluorophosphonate
  • HY-121616
    (R)-SLV 319
    Antagonist
    (R)-SLV 319 is a potent and selective cannabinoid receptor 1 (CB1) antagonist with a Ki value of 894 nM. (R)-SLV 319 is a dextrorotatory counterpart of SLV 319
    (R)-SLV 319
  • HY-145196
    RTICBM-189
    Modulator 99.73%
    RTICBM-189 is a potent, brain-penetrant allosteric modulator of the cannabinoid type-1 (CB1) receptor with a pIC50 of 7.54 in Ca2+ mobilization assay. RTICBM-189 has pIC50s of 5.29 and 6.25 for hCB1 and mCB1, respectively. RTICBM-189 significantly and selectively attenuates the reinstatement of the addictive agent-seeking behavior in rats.
    RTICBM-189
  • HY-168734
    CB2 receptor agonist 9
    Agonist
    CB2 receptor agonist 9 (Compound 33) is an orally active agonist for cannabinoid receptor 2 (CB2 receptor) with an EC50 of 16.2 nM. CB2 receptor agonist 9 inhibits the expression of TNF-α, IL-1β and IL-6, exhibits anti-inflammatory efficacy in DDS (HY-116282)-induced mouse acute colitis model.
    CB2 receptor agonist 9
  • HY-172568
    (±)5(6)-EET Ethanolamide
    Agonist
    (±)5(6)-EET Ethanolamide is a metabolite of Anandamide (HY-10863) generated via oxidation by cytochrome P450 enzymes. (±)5(6)-EET Ethanolamide is also a selective cannabinoid receptor 2 (CB2) agonist. (±)5(6)-EET Ethanolamide has Ki values of 11.4 μM and 8.9 nM for human CB1 and CB2, respectively . (±)5(6)-EET Ethanolamide can be used in research on immunomodulation and neuroinflammation.
    (±)5(6)-EET Ethanolamide
  • HY-125407S
    Palmitoyl serinol-d5
    Palmitoyl serinol-d5 is the deuterium labeled Palmitoyl serinol. Palmitoyl serinol (N-Palmitoyl serinol) is an analog of the endocannabinoid N-palmitoyl ethanolamine (PEA). Palmitoyl serinol improves the epidermal permeability barrier in both normal and inflamed skin.
    Palmitoyl serinol-d<sub>5</sub>
  • HY-161311
    AChE/BChE-IN-18
    Antagonist
    AChE/BChE-IN-18 (Compound 4g) is a dual inhibitor of AChE/BChE , with a IC50 value of 0.315 μM for AchE. AChE/BChE-IN-18 is also a CB2R antagonist with a Ki value of 31 nM. AChE/BChE-IN-18 has neuroprotective activity.
    AChE/BChE-IN-18
  • HY-128040
    Virodhamine hydrochloride
    Antagonist
    Virodhamine (hydrochloride) is a cannabinoid CB1 receptor partial agonist and cannabinoid CB2 receptor full agonist.
    Virodhamine hydrochloride
  • HY-W011040
    LY320135
    Antagonist
    LY320135 is a potent and selective antagonist of CB1 receptor, with a Ki of 141 nM. LY320135 also binds to 5-HT2 and muscarinic receptors with Kis of 6.4 μM and 2.1 μM, respectively. LY320135 exhibits neuroprotective effect.
    LY320135
  • HY-178176
    PROTAC CB1R Degrader-1
    Degrader
    PROTAC CB1R Degrader-1 is a potent and selective CB1R PROTAC degrader that exploits the ubiquitin-proteasome system (UPS) achieving a DC50 of 3.37 μM in MCF-7 cells and showing no impact on CB2R. PROTAC CB1R Degrader-1 reduces CB1R-associated downstream signaling (p-AKT, p-ERK, BCL2, and MCM5), thereby inhibiting breast cancer cell proliferation and inducing apoptosis. PROTAC CB1R Degrader-1 can be used for breast cancer research. (Blue: CRBN ligand (HY-41547); Black: linker (HY-178198); Pink: CB1R ligand (HY-134497)).
    PROTAC CB1R Degrader-1
  • HY-167865
    O-1269
    Agonist
    O-1269 is a partial agonist of cannabinoid receptor 1 (CB1R) with a Ki of 32 nM. O-1269 shows analgesic effects.
    O-1269
  • HY-133533
    O-2050
    Antagonist
    O-2050 is a high affinity cannabinoid CB1 receptor antagonist with a Ki of 2.5 nM. O-2050 inhibits cannabinoid CB2 receptor (Ki=0.2 nM). O-2050 can cause locomotor stimulation in mice.
    O-2050
  • HY-121545
    CB-52
    Antagonist
    CB-52 is the ligand and neutral antagonist of CB2 cannabinoid receptor.
    CB-52
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.